Macrocytosis after nucleoside-containing HIV treatment regimens

Kyle Petersen; Braden R. Hale; Mark R. Wallace

Macrocytosis after nucleoside-containing HIV treatment regimens

Kyle Petersen^*, Braden R. Hale, Mark R. Wallace

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Macrocytosis occurs with HIV therapies containing zidovudine (AZT) and stavudine (d4T) and may help assess adherence. Occurrence in antiretroviral therapy regimens without these agents or when they are added to multidrug antiretroviral therapy is unknown. We retrospectively evaluated change in mean corpuscular volume for 590 patients at 90 days after initiating therapy. Zidovudine and stavudine caused significant increases in mean corpuscular volume, similar to previous studies, whereas didanosine (ddI) did not. Addition of a protease inhibitor and or lamivudine did not significantly change the mean corpuscular volume.

Original language	English
Pages (from-to)	65-67
Number of pages	3
Journal	Infectious Diseases in Clinical Practice
Volume	13
Issue number	2
State	Published - Mar 2005
Externally published	Yes

Cite this

@article{55fe8885b57d44f2b30812810c97f2cb,

title = "Macrocytosis after nucleoside-containing HIV treatment regimens",

abstract = "Macrocytosis occurs with HIV therapies containing zidovudine (AZT) and stavudine (d4T) and may help assess adherence. Occurrence in antiretroviral therapy regimens without these agents or when they are added to multidrug antiretroviral therapy is unknown. We retrospectively evaluated change in mean corpuscular volume for 590 patients at 90 days after initiating therapy. Zidovudine and stavudine caused significant increases in mean corpuscular volume, similar to previous studies, whereas didanosine (ddI) did not. Addition of a protease inhibitor and or lamivudine did not significantly change the mean corpuscular volume.",

author = "Kyle Petersen and Hale, {Braden R.} and Wallace, {Mark R.}",

year = "2005",

month = mar,

language = "English",

volume = "13",

pages = "65--67",

journal = "Infectious Diseases in Clinical Practice",

issn = "1056-9103",

number = "2",

}

TY - JOUR

T1 - Macrocytosis after nucleoside-containing HIV treatment regimens

AU - Petersen, Kyle

AU - Hale, Braden R.

AU - Wallace, Mark R.

PY - 2005/3

Y1 - 2005/3

N2 - Macrocytosis occurs with HIV therapies containing zidovudine (AZT) and stavudine (d4T) and may help assess adherence. Occurrence in antiretroviral therapy regimens without these agents or when they are added to multidrug antiretroviral therapy is unknown. We retrospectively evaluated change in mean corpuscular volume for 590 patients at 90 days after initiating therapy. Zidovudine and stavudine caused significant increases in mean corpuscular volume, similar to previous studies, whereas didanosine (ddI) did not. Addition of a protease inhibitor and or lamivudine did not significantly change the mean corpuscular volume.

AB - Macrocytosis occurs with HIV therapies containing zidovudine (AZT) and stavudine (d4T) and may help assess adherence. Occurrence in antiretroviral therapy regimens without these agents or when they are added to multidrug antiretroviral therapy is unknown. We retrospectively evaluated change in mean corpuscular volume for 590 patients at 90 days after initiating therapy. Zidovudine and stavudine caused significant increases in mean corpuscular volume, similar to previous studies, whereas didanosine (ddI) did not. Addition of a protease inhibitor and or lamivudine did not significantly change the mean corpuscular volume.

UR - http://www.scopus.com/inward/record.url?scp=14844316653&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:14844316653

SN - 1056-9103

VL - 13

SP - 65

EP - 67

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

IS - 2

ER -

Macrocytosis after nucleoside-containing HIV treatment regimens

Abstract

Fingerprint

Cite this